Home » Newsletters » BioWorld Science

BioWorld Science

April 15, 2009

View Archived Issues

Ad2/HIF-1alpha/VP16 not effective in treating intermittent claudication

Studies show benefit of preprocedure atorvastatin loading in patients undergoing PCI

Increased malapposition seen with paclitaxel-eluting stent in acute myocardial infarction patients

Preliminary results from phase I/II study of BL-1040 myocardial implant presented

Bayer describes novel substituted tricyclic compounds for cancer treatment

Novel cytotoxic xanthone compounds claimed by Bristol-Myers Squibb

Roche claims novel NK3 receptor antagonists

Sanofi-aventis and Mitsubishi Tanabe Pharma claim novel tau protein kinase inhibitors

Novel compounds for the treatment of diabetes discovered by Kyorin and ActivX

Merck KGaA launches Lodotra in Germany

BioMS receives positive safety review for phase III multiple sclerosis trial

Osprey initiates phase Ib trial in IgA nephropathy

Phase II study reveals activity of OZ1 gene therapy in HIV patients

BioVex commences OncoVEX phase III metastatic melanoma trial

BioSante launches Elestrin in the U.S.

SC-599 well tolerated, induces protective immune responses in phase II study

Strativa provides product pipeline update for ODFS

Tobira Therapeutics initiates proof-of-concept study with TAK-652 for HIV

FDA grants orphan drug designation for Paclical in ovarian cancer

Jubilant and Orion sign drug discovery partnership

ImmuneRegen and University of Rochester to examine Homspera in lethal radiation exposure

Oxygen and Hospira sign development and commercial supply agreement for Oxycyte

Anesthetic/sedative CNS-7056 begins phase II

Sanofi-aventis to acquire BiPar Sciences

EVT-302 shows no benefit as aid to smoking cessation

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
ASH 2025: Ianalumab data offer break from chronic ITP therapy
BioWorld
Novartis AG’s monoclonal antibody, ianalumab (VAY-736), when added to standard-of-care eltrombopag, extended disease control of primary immune thrombocytopenia...